COMMUNIQUÉS West-GlobeNewswire

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built [...]
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
14/05/2026
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) ( [...]
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
14/05/2026
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
14/05/2026
Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
14/05/2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
14/05/2026
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in [...]
Administrative Experience Emerges as Key Pressure Point for Self-Funded Plans, Brighton Health Plan Solutions Survey Finds
14/05/2026
New report shows employee satisfaction remains high, but trust can break down when administrative friction gets in the way NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Self-funded health plans are working for many health [...]
ApolloMD Recognized as One of the Best Places to Work in Healthcare in 2026
14/05/2026
ATLANTA, May 14, 2026 (GLOBE NEWSWIRE) -- ApolloMD has been selected by Modern Healthcare 2026 Best Places to Work in Healthcare , recognizing healthcare organizations that foster strong workplace culture, support [...]
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
14/05/2026
Data spans seven presentations across both solid tumors and hematologic malignancies , providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib [...]
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
14/05/2026
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide
14/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026
14/05/2026
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced [...]
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
14/05/2026
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition [...]
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
14/05/2026
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development Robust reductions in tau [...]
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
14/05/2026
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas [...]
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third [...]
Ipsen présente la corabotase, un neuro-inhibiteur recombinant (RNI™) « premier de sa classe », lors du symposium SCALE
14/05/2026
La corabotase est la première molécule expérimentale d’une nouvelle classe de neuro-inhibiteurs recombinants, RNI TM , telle que reconnue par l’OMS et l’USAN* Les données de phase II concernant les rides glabellaires ( [...]
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
14/05/2026
Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNI TM , as recognized by the WHO and USAN Phase II data in glabellar (frown) lines to be featured as a late- [...]
Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership to Advance AI-Powered Chronic Disease Care
14/05/2026
SHANGHAI, May 14, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Shanghai Tenry Pharmaceutical Co., Ltd. (“Tenry [...]

Pages